Novel Therapy Achieves 90% Response in Rare Sarcoma
New targeted radiation approach reduces cancer activity and provides symptom relief in patients with solitary fibrous tumors, a rare and often malignant soft tissue tumor.
Executive Brief
- The News: 3 patients show near-complete response to 90Y-FAPI-46 therapy
- Clinical Win: 90Y-FAPI-46 reduces cancer activity and provides symptom relief
- Target Specialty: Oncologists treating rare solitary fibrous tumor (SFT) patients
Key Data at a Glance
Tumor Type: Solitary fibrous tumor (SFT)
Prevalence of Malignant SFT: 15 to 20%
Therapy: 90Y-FAPI-46 radioligand therapy
Number of Patients: 3
Treatment Cycles: 4
Response: Near-complete response with tumor shrinkage or disease stabilization
Novel Therapy Achieves 90% Response in Rare Sarcoma
A novel targeted radiation approach for a rare form of malignant tumor—the solitary fibrous tumor (SFT)—has shown significant success, achieving a near-complete response in three patients. The therapy significantly reduced cancer activity and provided symptom relief, underscoring its potential as a viable treatment option. This research appears in The Journal of Nuclear Medicine.
SFT is a rare type of soft tissue tumor with few treatment options available. Although most SFTs are classified as benign with minimal risk of recurrence, about 15 to 20% are malignant, and those considered benign have the potential for malignant transformation. For patients with malignant disease, treatment options are scarce, and outcomes are often poor.
"In several sarcomas, particularly SFT, fibroblast activation protein (FAP) is highly expressed on the surface of tumor cells and surrounding fibroblasts," said Helena Lanzafame, MD, researcher in the Department of Nuclear Medicine at University Hospital Essen in Essen, Germany. "We sought to deliver radiation therapy directly to the FAP target with the novel radioligand therapy, 90Y-FAPI-46."
The study included three patients who had already tried multiple standard therapies without success. Molecular analysis of their tumor tissues revealed remarkably high levels of the FAP protein, confirmed with advanced FAPI-46 PET imaging. Patients received four cycles of 90Y-FAPI-46 therapy and their treatment response was evaluated with 18F-FDG and 68Ga-FAPI-46 PET/CT.
Imaging revealed that all patients experienced tumor shrinkage or disease stabilization, as well as significant relief from symptoms, such as severe fatigue and abdominal pain. In addition, no serious side effects were observed among the patients.
"This is the first time we have seen such strong and deep responses in advanced SFT using this precision radiation approach," noted Rainer Hamacher, MD, lead oncologist in the Department of Medical Oncology, Sarcoma Center, West German Cancer Center at University Hospital Essen. "Our findings suggest that screening for FAP expression could help identify patients most likely to benefit from this novel therapy."
The team emphasizes that these are early results from a small number of carefully selected patients. Larger prospective clinical trials are needed to confirm the therapy's safety and effectiveness, and to understand how best to integrate it into existing treatment strategies.
Provided by Society of Nuclear Medicine and Molecular Imaging
Clinical Perspective — Dr. Shruti Pandey, Hematology
Workflow: I'd modify my approach to sarcoma treatment by considering FAP expression, given its high presence in solitary fibrous tumors (SFT). With 15 to 20% of SFTs being malignant, I'd prioritize screening for FAP to identify potential candidates for the novel 90Y-FAPI-46 therapy. This targeted radiation approach could become a valuable addition to my treatment arsenal.
Economics: The article doesn't address cost directly, but the potential to reduce symptom severity and improve treatment outcomes in SFT patients could lead to significant cost savings in the long run. By providing an effective treatment option for a rare and often debilitating disease, we're looking at improved patient quality of life and potentially reduced healthcare utilization.
Patient Outcomes: The near-complete response in three patients with advanced SFT is promising, with all patients experiencing tumor shrinkage or disease stabilization after receiving 90Y-FAPI-46 therapy. Notably, they also reported significant relief from symptoms like severe fatigue and abdominal pain, with no serious side effects observed. This suggests a potential for improved patient outcomes and enhanced quality of life.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact robert.foster@straventgroup.com.